Correlation Between Senzime AB and XSpray Pharma

Can any of the company-specific risk be diversified away by investing in both Senzime AB and XSpray Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Senzime AB and XSpray Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Senzime AB and XSpray Pharma AB, you can compare the effects of market volatilities on Senzime AB and XSpray Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Senzime AB with a short position of XSpray Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Senzime AB and XSpray Pharma.

Diversification Opportunities for Senzime AB and XSpray Pharma

0.16

Correlation Coefficient

Senzime AB  XSpray Pharma

Average diversification

The 3 months correlation between Senzime and XSpray is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Senzime AB and XSpray Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on XSpray Pharma AB and Senzime AB is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Senzime AB are associated (or correlated) with XSpray Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of XSpray Pharma AB has no effect on the direction of Senzime AB i.e., Senzime AB and XSpray Pharma go up and down completely randomly.

Pair Corralation between Senzime AB and XSpray Pharma

Assuming the 90 days trading horizon Senzime AB is expected to under-perform the XSpray Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Senzime AB is 1.11 times less risky than XSpray Pharma. The stock trades about -0.12 of its potential returns per unit of risk. The XSpray Pharma AB is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  4,705  in XSpray Pharma AB on September 14, 2024 and sell it today you would lose (255.00) from holding XSpray Pharma AB or give up 5.42% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Senzime AB  vs.  XSpray Pharma AB

Senzime AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Senzime AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

XSpray Pharma AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days XSpray Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, XSpray Pharma is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Senzime AB and XSpray Pharma

The main advantage of trading using opposite Senzime AB and XSpray Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Senzime AB position performs unexpectedly, XSpray Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XSpray Pharma will offset losses from the drop in XSpray Pharma's long position.

The idea behind Senzime AB and XSpray Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.